Avivagen Receives U.S. Re-Orders For Oximunolâ„¢ Supplement
(via Thenewswire.ca)
OTTAWA, ONTARIO, May 9, 2013 - Avivagen Inc. (TSXV:VIV), a wellness company committed to developing and delivering products that support and enhance the health and quality of life for animals and the people who care for them, announces its receipt of U.S. re-orders for its Oximunol(TM) Chewable Tablets for Dogs.
These re-orders follow from the autumn, 2012 launch of Oximunol(TM) canine in the United States by Avivagen's U.S. distribution partner. The re-order is for both product sizes, the tablet containing 20 mg of OxC-beta for larger dogs and that containing 5 mg for smaller dogs. Financial details relating to the order will be disclosed in Avivagen's statements for the relevant fiscal quarter.
Graham Burton and Janusz Daroszewski commented as the technology's lead co-developers "It is gratifying to know U.S. dogs and their owners are experiencing the benefits of Avivagen's fully-oxidized carotenoids as found in Oximunol(TM). We look forward to further orders from our U.S. distributor and to expanding distribution into other countries - for both companion animal and livestock applications."
Cameron Groome, CEO and President of Avivagen also commented "This re-order is important to Avivagen as it follows the acquisition of our original U.S. distributor, Teva Animal Health, by Bayer Animal Health LLC, as announced in September, 2012 and completed in January, 2013. We're pleased with the completion of this transition and will provide our continuing support to their commercial efforts."
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol "VIV". The Company's goal is to develop and deliver scientifically-proven solutions that can truly benefit companion and food animals by taking advantage of natural mechanisms for maintaining optimal health. Avivagen's targeted markets include Pet Wellness and Livestock Productivity.
The company has sites located in partnership facilities of the National Research Council of Canada (NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward Island.
More information can be found at www.avivagen.com.
About OxC-beta
Avivagen's proprietary and patent-protected technology supports the body's own systems to maintain and enhance health, particularly by supporting immune function. Avivagen's commercial-stage application of its technology is Fully-Oxidized beta-Carotene (OxC-beta).
OxC-beta compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support the health of companion animals and for use in the global food animal market.
Research results indicate OxC-beta helps support immune function, which can result in meaningful overall health benefits. In pets, benefits are seen in overall vitality and energy, skin, coat and gastrointestinal wellness. Food Animal benefits include healthier growth, better utilization of feed and decreased mortality. In Food Animals, it is intended that use of OxC-beta avoids the feeding of antibiotics.
The first commercial product launched by Avivagen is Oximunol(TM) Chewables.
About Oximunol(TM) Chewables - "Optimized Health in a Chewable Tablet"
Oximunol(TM) Chewables is a scientifically-formulated chewable tablet that contains Avivagen's proprietary, patented active ingredient OxC-beta. Oximunol(TM) Chewables are currently available for dogs of all ages in the United States, working with a dog's own immune system to optimize overall health and well-being.
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Copyright (c) 2013 TheNewswire - All rights reserved.